Ethanolamine oleate is a salt of ethanolamine, a basic substance, and oleic acid. It is marketed under a trade name of Ethamoline as a sclerotic agent for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. In vitro studies revealed that ethanolamine oleate inhibits fibrin clot formation because of the Ca2+-chelating ability of its constituent ethanolamine. Nevertheless, from in vivo studies it was suggested that intravascular injection of ethamoline activates the local coagulation system. The activation may be accelerated by an acute inflammatory process provoked by oleate, which is supported by such clinical manifestations as mild fever, retrosternal pain leukocytosis and an increase in plasma fibrinogen level.

7β-hydroxycholesteryl-3-oleate has been shown to inhibit astrogliosis and intracranial glioblastoma growth. Local administration of 7β-hydroxycholesteryl-3-oleate inhibits growth of experimental rat C6 glioblastoma. These data suggest that 7β-hydroxycholesteryl-3-oleate might be useful for local glioblastoma chemotherapy. 7β-hydroxycholesteryl-3-oleate is a potent inhibitor of the endogenous cholesterol biosynthesis in brain showing a correlation between cholesterogenesis and reactive astrocyte proliferation. 7β-hydroxycholesteryl-3-oleate can reduce the astrocytic reaction following spinal cord injury, promoting the serotonergic reinnervation of a denervated territory. On 17 December 2010, orphan designation (EU/3/10/816) was granted by the European Commission to Intsel Chimos SA, France, for 7-beta-hydroxy cholesteryl-3-beta-oleate for the treatment of glioma. The substance is going to be injected directly into the brain tumour contained within liposomes, which are expected to carry the medicine into the glioma cells.

There is no information about biological and pharmacological application of lead maleate. It is known, that this is insoluble in water salt of lead and oleic acid. This substance is a toxic, with teratogenic and carcinogenic properties.